Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 4Terminated 3Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Melanoma 23Neoplasm Metastasis 14Leukemia, Myeloid, Acute 11Carcinoma, Renal Cell 10Neoplasms 8Kidney Neoplasms 8Skin Neoplasms 5Recurrence 5Leukemia 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Ovarian Neoplasms 4Lymphoma, Non-Hodgkin 4Colorectal Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Neuroblastoma 3Lymphoma, Follicular 3Congenital Abnormalities 3Carcinoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Prostatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Head and Neck Neoplasms 2Carcinoma, Merkel Cell 2

Interventions

Rituximab 59Cyclophosphamide 29fludarabine phosphate 20Bortezomib 16Filgrastim 15Tacrolimus 12Mycophenolic Acid 12Methotrexate 12Radiotherapy 11Peripheral Blood Stem Cell Transplantation 11Cyclosporine 11Antilymphocyte Serum 11Whole-Body Irradiation 10fludarabine 8Etoposide 8venetoclax 7sargramostim 7idelalisib 7ibritumomab tiuxetan 7Melphalan 7Lenalidomide 7Cord Blood Stem Cell Transplantation 7Busulfan 7Bendamustine Hydrochloride 7Vincristine 6Prednisone 6Granulocyte Colony-Stimulating Factor 6obinutuzumab 5Gemcitabine 5umbralisib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Follicular × Interleukin-2 × Clear all
NCT05336409 2025-12-18

ELiPSE-1

Century Therapeutics, Inc.

Phase 1 Terminated
28 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT00625729 2017-12-28

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Masonic Cancer Center, University of Minnesota

Phase 1/2 Terminated
6 enrolled 10 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT00100737 2006-02-06

Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)

Chiron Corporation

Phase 2 Terminated
300 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡